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Capsule: 
The focus of this review is to discuss the indications for ovarian tissue 
cryopreservation in young patients with cancer, and future potential 
uses for this tissue.  
Narrative Abstract: 
 
With increasing numbers of survivors of cancer in young people future 
fertility and ovarian function are important considerations that should 
be discussed before treatment commences. Some young people, by 
nature of the treatment they will receive, are at high risk of premature 
ovarian insufficiency and infertility. For them, ovarian tissue 
cryopreservation (OTC) is one approach to fertility preservation that 
remains both invasive and for young patients experimental. There are 
important ethical and consent issues that need to be explored and 
accepted before OTC can be considered established in children with 
cancer. In this review we have discussed a framework for patient 
selection which has been shown to be effective in identifying those 
patients at high risk of premature ovarian insufficiency (POI) and who 
can be offered OTC safely.  
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Introduction 
 
The number of survivors of childhood cancers has increased over the last 
four decades. In the USA, the five year actuarial survival rate of the age 
group 0-14 years for the period 1950-1954 was only 20% (1) whereas for 
the period 2008-2012, the crude survival rate (incidence less mortality 
per 100,000 children) was 87% (2). Across the EU, the crude death rate 
from cancer for the 0-14 age group has fallen from 3.9 per 100,000 in 
1997 to 2.1 per 100,000 in 2012 (3). The corollary to these 
improvements is that the general population contains a progressively 
larger proportion of survivors of childhood cancer (4), many of whom 
are at risk of multi-faceted chronic morbidity as a result of their 
successful treatment (5). Although many survivors of childhood cancer 
go on to have children, the potential loss of fertility is a frequent 
concern of both patients, their parents and medical carers (6). Some 
children, by nature of the treatment they will receive, are at high risk of 
infertility. For example, a large-scale study by the Childhood Cancer 
Survivor Study (CCSS) found that, compared to their siblings, the relative 
risk (RR) for survivors of ever being pregnant is 0.56 after 5-10 Gy to a 
field including the ovaries, with the RR falling to 0.18 after more than 10 
Gy to a field including the ovaries (7).  Recent data from the CCSS also 
suggest that the prevalence of subfertility, even where ovarian function 
is retained, is increased (8). The focus of this review is to discuss the 
indications for ovarian tissue cryopreservation in young patients with 
cancer, and future potential uses for this tissue.  
 
At diagnosis, all patients deserve an informed consultation about their 
fertility prognosis (9, 10). For some, their prognosis is uncertain, but for 
the majority of patients it is clear whether – for the individual – the risk 
of compromising fertility with first line treatment is low, medium or high 
(11). 
 
At the time of diagnosis, the young patient is often unwell, and the 
family is facing an extraordinarily difficult time. The patient is 
undergoing many complex investigations and procedures, and the 
treating pediatric team may be able to offer entry into complex research 
studies that require informed consent from the patient and the family. 
These investigations, procedures and discussions take time, and are 
challenging for the patient and their family. However, we believe that 
informed discussion about the fertility prognosis – while potentially an 
additional burden – can be a positive experience, even if a fertility 
preservation procedure is not indicated (because the assessed risk to 
future fertility is low) or indeed is not possible.    
 
It is, regrettably, clear that these discussions do not always take place 
(12, 13). Assessment of UK practice relating to information provision 
about the effects of cancer treatment on fertility and options for fertility 
preservation showed that discussions were less common with girls than 
with boys, with young age of the girl being the most common reason 
cited for not having such a discussion (10). The American Society of 
Clinical Oncology has produced two evidence-based recommendations 
for fertility preservation for patients with childhood cancer (14, 15). A 
recent study of compliance with these recommendations reported that 
none of 136 patients older than 13 years at their last visit were 
counselled on fertility preservation (16).  
  
 
  
Background 
 
The human ovary is active during childhood (17). Follicles are recruited 
towards maturation at all ages, differentiate to preantral and antral 
follicles, but – for pre-pubertal ages – in the absence of sufficient 
gonadotropic support undergo atresia before they reach pre-ovulatory 
sizes (18). We have devised an age-related model of the non-growing 
follicle (NGF) population in healthy females (Figure 1), and additionally 
calculated the age-related rates of recruitment of NGFs towards 
maturation (Figure 2) (19). Interestingly, the rate of recruitment peaks at 
around 14 – 15 years of age, irrespective of whether there is a high, 
medium or low ovarian reserve. In theory, the pre-pubertal ovary is an 
ideal candidate for ovarian tissue cryopreservation (OTC), with plentiful 
follicles available for cryopreservation and future re-implantation 
although there is evidence that the childhood ovary contains a 
significant proportion of morphologically abnormal follicles, that are lost 
in adolescence (20). No perfect index of ovarian reserve exists, but the 
best available indirect biomarker is anti-Müllerian hormone (AMH) 
(Figure 3)(21) which is of established value in adult women (22). 
However, its utility as an indirect marker of ovarian reserve in the pre-
pubertal child remains uncertain. There is some evidence that AMH in 
children newly diagnosed with cancer is lower than healthy age-matched 
children (23), with comparable data in adult women (24). The role for 
AMH in the assessment of ovarian reserve in young patients with cancer 
remains a subject of on-going research. 
 
Treatment with cytotoxic drugs inhibits follicular growth (18, 25, 26), but 
other mechanisms for the reduction of ovarian reserve have been 
suggested. Cyclophosphamide is known to increase the rate at which 
follicles are recruited towards maturation, leading to what has been 
termed ‘burnout’ of the NGF population (27). A recent in vitro study in a 
mouse model indicates that different chemotherapy drugs are likely to 
be cytotoxic to different cells in the ovary, with cisplatin and doxyrubicin 
affecting primarily oocytes and granulosa cells respectively (28). 
Irradiation to field that includes the ovaries in childhood causes 
permanent damage by destroying the small follicles (30, 31). It has been 
suggested that abdominal irradiation impairs follicle development as 
well as destroying small follicles (32). By modelling NGF decline with 
increasing age, we have shown that the LD50 of the human oocyte is less 
than 2 Gray (30) . This may be helpful in predicting the age at which 
premature ovarian insufficiency (POI) develops if the dose to the ovary 
furthest away from the radiation field can be calculated (31). While 
cytotoxic treatment may accelerate depletion of NGF pool, leading to 
impaired fertility and POI, analysis of a prospective cohort of young 
patients with cancer has shown that serum AMH can indicate POI even 
in very young girls, before conventional markers e.g. FSH are elevated 
(33).  
 
Radiation to a field that includes the pelvis (including total body 
irradiation) has been shown to impair uterine growth and blood flow. 
Those patients who have achieved a pregnancy but who have been 
exposed to radiation to the uterus have a very high incidence of late 
miscarriage, fetal growth restriction and premature birth (34-38). 
 
  
Potential Indications for Ovarian Tissue Cryopreservation. 
 
Ovarian tissue cryopreservation is one relevant approach to fertility 
preservation for the pre-pubertal girl facing treatment-induced loss of 
fertility, although ovarian shielding from radiotherapy and potentially 
oophoropexy may also be appropriate considerations (39). OTC is an 
invasive and still experimental procedure for young patients, requiring 
laparoscopic surgery.  Our practice is to take multiple ovarian cortical 
strips from one ovary if possible, rather than a whole ovary as advocated 
by some authorities (40). The importance of patient selection, 
considering the clinical need, patient and parental consent, and surgical 
risk in what are necessarily unwell children cannot be overstated.  We 
have previously described a framework for consideration of the issues 
that are relevant, divided into issues that are intrinsic to the patient (her 
age and general health, capacity for consent, and ovarian reserve), and 
extrinsic (notably the risk to her fertility of the treatment proposed) (9). 
The validity of the ‘Edinburgh criteria’ for OTC has recently been 
assessed (Table 1) (40). We have offered this procedure, performed 
laparoscopically, to girls with newly diagnosed cancer who met these 
criteria since 1996.  Only 34 (8%) of the 410 patients treated in a 
regional children’s cancer centre met the Edinburgh selection criteria 
and were offered ovarian tissue cryopreservation before starting cancer 
treatment. 13 patients declined the procedure and 21 consented, and 
the procedure was completed successfully in 20 patients of whom 14 
were available for assessment of ovarian function. The median age at 
the time of follow-up for the 20 patients was only 16·9 years (IQR 15·5–
21·8), however, of the 14 assessable patients who had successfully 
undergone OTC, six had developed POI at a median age of 13·4 years 
(IQR 12·5–14·6). Assessment of ovarian function was possible for 141 of 
the 376 patients who were not offered cryopreservation; only one of 
these patients had developed POI. The cumulative probability of 
developing POI after treatment was completed was significantly higher 
for patients who met the criteria for ovarian tissue cryopreservation 
than for those who did not (15-year probability 35% [95% CI 10–53] vs 
1% [0–2]; p<0·0001; hazard ratio 56·8 [95% CI 6·2–521·6] at 10 years) 
(Figure 4). While these criteria are proposed as a starting point for 
further research and refinement, they do appear to be a clinically useful 
guide to aid patient selection. Longer-term follow up will be necessary to 
assess later onset POI and the prevalence of subfertility of this cohort.  
 
  
Potential Indications for re-implantation of ovarian tissue. 
 
The key indication for re-implantation of ovarian tissue is for restoration 
of fertility. While the freeze/thaw followed by the re-implantation 
process causes attrition of about three quarters of the NGF population 
(41), over sixty live births have been reported after transplantation of 
cryopreserved ovarian tissue (42). The majority of women show 
restoration of ovarian activity by four months after transplantation, with 
live birth in about 25% (42). All these lives births derived from ovarian 
tissue had been taken from adult women. In a recent report (43) the 
authors have described a live birth in a woman with sickle-cell anaemia 
treated with a myeloblative conditioning regimen as part of a stem cell 
transplantation, after autograft of cryopreserved ovarian tissue taken at 
the age of 14 years, confirming the validity of this approach in 
adolescent as well as adult women.  
 
While restoration of fertility is the main indication for re-implantation of 
ovarian tissue to patients with POI, the ovary is also an endocrine organ 
and restoration of hormonal function may also be a valid indication. Re-
implantation of ovarian tissue for pubertal induction has also been 
described (44, 45), with in both cases pubertal development and onset 
of menses. Induction of puberty with exogenous steroid hormones 
either orally or trans-dermally is well established in pediatric endocrine 
practice, with the main guiding principal being slow increases in 
estrogen exposure and delayed progesterone administration. The re-
implantation of ovarian tissue in a hypergonadotrophic environment will 
result in ovulatory cycles with exposure to adult steroid concentrations 
much more rapidly than occurs physiologically, and waste of a finite 
number of germ cells (46). Additionally, in the cancer patient, there 
remains a possibility of recrudescence of the original cancer, particularly 
in hematological malignancies (47, 48). 
 
  
Ethical considerations 
 
OTC in the young patient with cancer offers ethical challenges for the 
patient, their family, and the treating team. The young patients 
themselves are usually unable to give informed consent for an 
experimental procedure. Therefore, in the case of OTC for young 
patients, informed consent is obtained from the parent or guardian. For 
an experimental procedure to be ethical in a child it must considered to 
be in the child’s best interests. At the time of presentation, the patient is 
often unwell and may be at increased risk of bleeding and/or infection 
from a laparoscopic procedure. However, if the chances of a cure are 
good, and if future fertility is likely to be compromised, it may be 
considered to be in the best interests of the child to have their ovarian 
tissue cryopreserved for future use. If the ovarian tissue is not taken 
before treatment commences, the opportunity to preserve fertility may 
have been lost and will certainly be compromised. If OTC were to be 
reclassified as established rather than experimental (15, 49), then the 
procedure may then be considered to be in the best interests of the 
child, and therefore consent from parent or guardian to be ethically 
justifiable (50-52). In some European countries, but not in the United 
Kingdom or United States of America, OTC is already considered an 
established procedure. Return of the tissue happens at a later date 
when the child is mature and able to give valid informed consent (9). In 
summary, obtaining ovarian tissue for cryopreservation remains 
experimental and in our Institution is carried out under the auspices of 
an ethically approved clinical trial.   
 
  
Conclusions 
OTC in children remains experimental, and is an invasive procedure 
requiring a general anesthetic, which may carry additional risks in the 
new young patient with cancer. There are important ethical and consent 
issues that need to be explored and accepted before OTC can be 
considered established in children with cancer. The majority of young 
patients with cancer will not have their fertility significantly 
compromised by their planned treatment and so patient selection is 
essential.  We have proposed a framework for patient selection which 
has been shown to be effective in identifying those patients at high risk 
of POI and who can be offered OTC safely.  
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Figures and Tables  
 
Figure 1. Normative model for NGF population. The best model for 
the establishment of the NGF population after conception, and the 
subsequent decline until age at menopause. The figure shows the dataset 
(n = 325), the model, the 95% prediction limits of the model, and the 95% 
confidence interval for the model. The horizontal axis denotes age in 
months up to birth at age zero, and age in years from birth to 51 years. 
Reprinted with permission (19). 
 
 
 
Figure 2.  Rates of NGF recruitment towards maturation. 
Each sub-figure describes the absolute number of NGFs recruited per 
month, for ages from birth to 55 years, based on population decline 
predicted by the ADC model. The red curve denotes recruitment for 
individuals whose decline is in line with the average age at menopause; 
maximum recruitment of 880 follicles per month occurs at 14 years 2 
months. The green curve denotes recruitment for individuals whose 
decline is in line with early age at menopause (the lower 95% prediction 
limit of the model); maximum recruitment of 104 follicles per month 
occurs at 14 years 2 months. The yellow curve denotes recruitment in line 
with late age at menopause (the upper 95% prediction limit of the model); 
maximum recruitment of 7,520 follicles per month occurs at 14 years 2 
months. Reprinted with permission (19). 
 
 
 
 
 
Figure 3. The normal range for serum AMH in girls and women. 
The red line is the log-unadjusted validated AMH model using IBC assay 
values. The blue and green lines are the 68% and 95% prediction limits 
for the model (plus and minus one and two standard deviations 
respectively). Reprinted with permission (21). 
 
 
 
 
 
 
Figure 4. Cumulative probabilities of not having premature ovarian 
insufficiency. Reprinted with permission (40). 
  
  
 
Table 1. The Edinburgh OTC selection criteria. Reprinted with 
permission (40). 
 
Age younger than 35 years 
No previous chemotherapy or radiotherapy if aged 15 years or 
older at diagnosis, but mild, non-gonadotoxic chemotherapy 
acceptable if younger than 15 years 
A realistic chance of surviving for 5 years 
A high risk of premature ovarian insufficiency (>50%) 
Informed consent (from parents and, where possible, patient) 
Negative serology results for HIV, syphilis, and hepatitis B 
Not pregnant and no existing children 
 
 
